MTFR2 and neoplasm: Based on the above experimental results, we believe that AS/BJO-NEs exert their anti-OSCC biological effects by downregulating the CDK1 expression and then regulating a series of tumor-related processes mediated by MTFR2, especially the inhibitory effect on the EMT process.